Condition: Clonal Cytopenia of Undetermined Significance · High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements · Recurrent Diffuse Large B-Cell Lymphoma · Sponsor: Mayo Clinic
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells. Arms A, B, C, and D are closed to enrollment.
This description comes directly from the study's public registry record.
Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic Health Systems-Mankato | Mankato, Minnesota, United States | Not Yet Recruiting |
| Mayo Clinic in Rochester | Rochester, Minnesota, United States | Recruiting |
| Mayo Clinic Health System-Eau Claire Clinic | Eau Claire, Wisconsin, United States | Not Yet Recruiting |
| Mayo Clinic Health System-Franciscan Healthcare | La Crosse, Wisconsin, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03418038